GroupHealth RESEARCH INSTITUTE

Bridging the gap between research and patient care

2011 ANNUAL REPORT
We have an opportunity and a moral duty to rescue American health care the only way it can be rescued—by improving it.

Donald M. Berwick, MD, MPP
Senior Fellow, Center for American Progress

Like building a bridge, conducting health research is an optimistic act. We start by identifying gaps that can stop progress in its tracks. Then we forge a solid and expanding base of knowledge that all stakeholders—patients, clinicians, purchasers, policymakers, and others—can use to reach their goals.

At Group Health Research Institute (GHRI), 2011 was a good year for bridge building. We made major strides in our evolution as a “learning health care system”—where research and practice are meaningfully integrated, and advances in science are designed to catalyze advances in care. Our progress is driven largely by:

- Collaboration among Group Health researchers, clinicians, administrators, and patients. Together we conduct nonproprietary, public-interest research within an integrated health system and develop real-world innovations that serve both Group Health and the nation.
- An interdisciplinary approach among highly engaged faculty and staff. We form teams of physician scientists, health services researchers, epidemiologists, biostatisticians, and behavioral health experts from GHRI and other institutions to address the country’s most common health problems.
- Partnerships in multi-site research networks. Groups such as the HMO Research Network, the Food and Drug Administration’s Mini-Sentinel Initiative, and the Breast Cancer Surveillance Consortium add statistical power, diversity, and expertise.
- Committed sponsorship. Funders such as the National Institutes of Health, the Agency for Healthcare Research and Quality, the Group Health Foundation, and the Robert Wood Johnson Foundation continue to support our work.

2011 was also a time of great uncertainty over federal funding for health care and research. Still, GHRI ended 2011 with annual grant revenue slightly higher than ever before and a stable outlook for the coming year. Today’s economic and political climate makes future resources tough to predict. But the U.S. health care system is rife with gaps in knowledge that GHRI and its partners aim to address.

We see, for example, vast data stores that can be mined to inform better approaches to care. We recognize the distance between high health care spending and needs that go unmet when the health care system wastes resources or misaligns incentives. We see how some Americans are harmed by too much treatment while others can’t get the most basic services.

At GHRI, we’re bridging gaps to innovate and improve care, knowing we can help the nation build a better health care system.

Eric B. Larson, MD, MPH
Executive Director, Group Health Research Institute
Vice President for Research, Group Health

Cover photo: Assistant Investigator Sascha Dublin, MD, PhD, is one of several Group Health Research Institute faculty who also practice medicine at Group Health. Dr. Dublin, who holds a five-year Paul B. Beeson Career Development Award in Aging Research from the National Institute on Aging, is a primary care doctor whose research focuses on medication safety in older adults.

Eric B. Larson, MD, MPH
Executive Director, Group Health Research Institute
Vice President for Research, Group Health
Opioid-prescribing safety: Finding real-world solutions for a nationwide epidemic

In April 2011, federal officials called for “urgent action” to curb a national epidemic of prescription drug abuse. The evidence was clear: Fatal overdoses involving prescribed opioids quadrupled from 1999 to 2009, climbing to almost 16,000 U.S. deaths annually—more than cocaine and heroin overdoses combined. What wasn’t clear was how to combat this growing threat. But thanks to Group Health’s pioneering opioid-prescribing safety initiative—and a corresponding evaluation led by GHRI Senior Investigator Michael Von Korff, ScD—we’re quickly learning new ways to improve patient safety.

Drugs overdose deaths
Prescribed opioids compared to cocaine and heroin

<table>
<thead>
<tr>
<th>Year</th>
<th>Cocaine</th>
<th>Heroin</th>
</tr>
</thead>
<tbody>
<tr>
<td>99</td>
<td>2000</td>
<td>1000</td>
</tr>
<tr>
<td>00</td>
<td>5000</td>
<td>3000</td>
</tr>
<tr>
<td>01</td>
<td>7000</td>
<td>4000</td>
</tr>
<tr>
<td>02</td>
<td>9000</td>
<td>5000</td>
</tr>
<tr>
<td>03</td>
<td>11000</td>
<td>6000</td>
</tr>
<tr>
<td>04</td>
<td>13000</td>
<td>7000</td>
</tr>
<tr>
<td>05</td>
<td>15000</td>
<td>8000</td>
</tr>
<tr>
<td>06</td>
<td>17000</td>
<td>9000</td>
</tr>
<tr>
<td>07</td>
<td>19000</td>
<td>10000</td>
</tr>
<tr>
<td>08</td>
<td>21000</td>
<td>11000</td>
</tr>
<tr>
<td>09</td>
<td>23000</td>
<td>12000</td>
</tr>
</tbody>
</table>

Number of deaths by drug

Opioid analgesic
Cocaine
Heroin

Opioid overdose risk (fatal & non-fatal)
By average daily dose of medically prescribed opioids

Risk ratio

- 0.04% 1-19 mg
- 0.16% 20-49 mg
- 0.26% 50-99 mg
- 0.4% 100+ mg

Average daily dose in morphine equivalents

Overdose is 1.79% more likely at the highest doses

- 1.79% patients overdose
- 0.68% patients overdose

Mobilizing a learning health care system

“On April 11, 2011, federal officials called for ‘urgent action’ to curb a national epidemic of prescription drug abuse. The evidence was clear: Fatal overdoses involving prescribed opioids quadrupled from 1999 to 2009, climbing to almost 16,000 U.S. deaths annually—more than cocaine and heroin overdoses combined. What wasn’t clear was how to combat this growing threat. But thanks to Group Health’s pioneering opioid-prescribing safety initiative—and a corresponding evaluation led by GHRI Senior Investigator Michael Von Korff, ScD—we’re quickly learning new ways to improve patient safety.”

Before the new clinical guideline was launched, few of Group Health’s 7,000 patients with long-term opioid prescriptions had documented care plans. By the end of 2011, 96 percent of them did—extraordinary results that are helping answer the nation’s call for promising solutions to the prescription drug-abuse epidemic. But it doesn’t end there.

“We’re prescribing lower doses of opioids overall, and we’re doing much more urine drug screening,” says Dr. Trescott. “We’re also having honest, in-depth discussions about opioids with our patients before treatment starts. The system has been fair, respectful, honest, and transparent.”

Before the new clinical guideline was launched, nearly 80% of targeted patients had documented care plans. By April’s federal call to action, nearly 90% of targeted patients had documented care plans.

“We make changes in real-world practice and study them, we not only clarify goals and expectations, but we also pursue federal funding to continue evaluating the initiative’s impact on standardization of care and the rate of adverse events.”

Helping Group Health harness opportunities for swift bidirectional learning—where evidence informs practice and practice informs evidence—is integral to the work of Associate Medical Director of Research Translation Robert J. Reid, MD, PhD, who assumed this role early in 2011. Also a GHRI associate investigator, Dr. Reid leads Group Health’s ongoing evaluation of the patient-centered medical home rollout in primary care—while keeping his eyes peeled for other opportunities to study care innovations in real-world practice.

A prime example: When the organization undertook a comprehensive clinic facility redesign initiative in 2011, Dr. Reid and his research team used funds from Group Health and GHRI to quickly develop a baseline prescription drug-abuse epidemic. But it doesn’t end there.

“When we make changes in real-world practice and study them, we not only learn ways to address a particular problem, we learn strategies that can be generalized to other important practice changes and other systems,” explains Dr. Von Korff. “It’s learning that reaches well beyond Group Health.”

And his research team are pursuing federal funding to continue evaluating the initiative’s impact on standardization of care and the rate of adverse events.

“We’re prescribing lower doses of opioids overall, and we’re doing much more urine drug screening,” says Dr. Trescott. “We’re also having honest, in-depth discussions about opioids with our patients before treatment starts. The system has been fair, respectful, honest, and transparent.”

Before the new clinical guideline was launched, few of Group Health’s 7,000 patients with long-term opioid prescriptions had documented care plans. By the end of 2011, 96 percent of them did—extraordinary results that are helping answer the nation’s call for promising solutions to the prescription drug-abuse epidemic. But it doesn’t end there.

“When we make changes in real-world practice and study them, we not only learn ways to address a particular problem, we learn strategies that can be generalized to other important practice changes and other systems,” explains Dr. Von Korff. “It’s learning that reaches well beyond Group Health.”

And his research team are pursuing federal funding to continue evaluating the initiative’s impact on standardization of care and the rate of adverse events.

“We’re prescribing lower doses of opioids overall, and we’re doing much more urine drug screening,” says Dr. Trescott. “We’re also having honest, in-depth discussions about opioids with our patients before treatment starts. The system has been fair, respectful, honest, and transparent.”

Before the new clinical guideline was launched, few of Group Health’s 7,000 patients with long-term opioid prescriptions had documented care plans. By the end of 2011, 96 percent of them did—extraordinary results that are helping answer the nation’s call for promising solutions to the prescription drug-abuse epidemic. But it doesn’t end there.

“When we make changes in real-world practice and study them, we not only learn ways to address a particular problem, we learn strategies that can be generalized to other important practice changes and other systems,” explains Dr. Von Korff. “It’s learning that reaches well beyond Group Health.”

And his research team are pursuing federal funding to continue evaluating the initiative’s impact on standardization of care and the rate of adverse events.

“We’re prescribing lower doses of opioids overall, and we’re doing much more urine drug screening,” says Dr. Trescott. “We’re also having honest, in-depth discussions about opioids with our patients before treatment starts. The system has been fair, respectful, honest, and transparent.”
Breast cancer screening: A trio of innovators shines light on the evidence women need

Few would argue the value of screening mammography in preventing deaths from breast cancer. But serious questions remain about how best to balance screening’s benefits with its potential harms, including false-positive test results, overdiagnosis leading to invasive treatment for non-life-threatening conditions, and repeated exposure to medical radiation.

The uncertainty has both the U.S. Preventive Services Task Force and the Institute of Medicine calling for better evidence about screening outcomes and the myriad factors that affect them. Through groundbreaking research with the Breast Cancer Surveillance Consortium (BCSC), Dr. Diana Miglioretti, PhD, and Diana S.M. Buist, PhD, MPH, and Assistant Investigator Rebecca Hubbard, PhD, provided that evidence in 2011.

The BCSC is a national network of seven mammography registries with links to tumor and/or pathology registries. Established in 1994, it is the nation’s largest longitudinal collection of breast imaging data—a one-of-a-kind resource that lets researchers worldwide answer timely questions about benefits and risks of breast cancer screening.

One recent example: annual mammograms have long been worldwide answer timely questions about benefits and risks of breast cancer screening.

False positives lead to $1.6 billion in health care costs each year—while causing stress and anxiety for millions of women. That’s why Dr. Hubbard and colleagues used BCSC data to examine false-positive results from screening mammograms for 169,000 women. In the October 18, 2011 Annals of Internal Medicine, they reported that, on average, more than half of women screened yearly for a decade had a false-positive result—and that having prior mammograms for comparison cut the odds of a false-positive in half. Screening every two years instead of annually lowered the false-positive rate by a third. Starting screening at age 50 instead of age 40 also lowered the lifetime risk of false positives.

“The BCSC’s goal is to take screening recommendations from one-size-fits-all to personalized,” Dr. Miglioretti explains. Thanks to the Consortium’s new $20 million Program Project grant from the National Cancer Institute, that goal is within reach.

GHRI’s statistical leadership brings data to life

Integral to the BCSC’s success is its ability to collect, store, and analyze data across diverse registries. By 2011’s close, the BCSC database included 9.5 million mammograms, 2.3 million women, and 114,000 breast cancer cases. Those quantities keep rising, as do the numbers of grant applications and publications supported by BCSC data—more than 70 and 400, respectively, to date. Most important, BCSC data play an essential role in breast cancer screening policy decisions and clinical recommendations. How do data achieve such influential reach?

“Based on our data, increasing mammograms be...”

Acknowledgement

Above: Drs. Miglioretti, Buist, and Hubbard made news in 2011 with cutting-edge research from the Breast Cancer Surveillance Consortium (BCSC) that shed light on important factors affecting breast cancer screening outcomes. Several other GHRI faculty play a key role in the BCSC research program, including Research Associate Erin Aibling Bowles, MPH, and Senior Biostatistician Laura Kihlkaa, MS (not pictured).
Out in front: Findings from ‘first-ever’ studies in 2011

Drug safety research guides therapy for Alzheimer’s

You wouldn’t hit the brakes on your car while pressing the gas—or wash down a sleeping pill with espresso. Yet many patients taking common Alzheimer’s disease medications called cholinesterase inhibitors are also prescribed drugs with anticholinergic properties, including some medicines for allergies, urinary incontinence, and depression. The problem? The two types of drugs antagonize each other such that neither medication works.

Until a 2011 study led by GHRI Associate Investigator Denise Boudreau, PhD, RPh, and e-published in the Journal of the American Geriatrics Society, little was known about how often patients use the two types of drugs simultaneously and the harms this might cause. With colleagues from Kaiser Permanente Colorado—GHRI’s longtime HMO Research Network partner—Dr. Boudreau analyzed electronic pharmacy records from nearly 6,000 patients aged 50 or older who took cholinesterase inhibitors between 2000 and 2007. The team found that more than one-third took the cholinesterase inhibitors while also taking other drugs that may oppose them—and one-quarter of those did so for more than a year. But they found no link between concurrent use and nursing home admissions or death.

While the latter finding is reassuring, Dr. Boudreau emphasizes that “when a treatment has side effects and outcomes they don’t want, five- or 10-fold increases in harm are possible.” The team recommended that patients discuss drug interactions with their care providers and consider alternative treatment options.

Visit us at: GroupHealthResearch.org to learn more about new findings and ongoing studies.

Shared decision making: Videos turn up the volume

With obesity dangerously on the rise in the United States, it’s not surprising that bariatric surgeries have increased 20-fold since 1996: from 9,400 to more than 220,000. The surgery can help severely obese people improve obesity-linked diseases such as type 2 diabetes, but its long-term outcomes remain uncertain.

“When a treatment has many pros and cons—as bariatric surgery does—individual patient preferences should play an even larger role than usual in treatment decisions,” says GHRI Associate Investigator David Arterburn, MD, MPH. Publishing in Obesity in August 2011, Dr. Arterburn and colleagues from GHRI, Harvard, and the University of Washington reported on the first-ever randomized controlled trial of shared decision making for weight loss surgery. In shared decision making, patients receive information about possible risks and benefits of different treatment choices and talk with their care providers about the side effects and outcomes they are most comfortable with. Then they make the choice that’s right for them.

According to Dr. Arterburn’s findings, using a video-based decision aid can enhance the shared decision-making process. Among 152 Group Health patients considering bariatric surgery, those who watched such a video made choices that were more in line with their preferences, needs, and values. They also knew more about the treatment’s risks, benefits, and likely outcomes than did those who only read an educational booklet.

Massage, yoga, and stretching: Discovering paths to back pain relief

Chronic back pain is a common condition with many treatments, but it’s hard to find solid evidence about which work best and cause the fewest side effects. In 2011, Senior Investigators Daniel Cherkin, MPH, led two studies on alternative treatments for chronic low back pain that made strides toward better answers—while also making headlines.

In the July 5 Annals of Internal Medicine, their team reported on the first back pain study to compare structural and relaxation (Swedish) massage. Their randomized controlled trial of 400 Group Health patients showed that both types of massage worked equally well to ease chronic low back pain, while causing few side effects. The team followed that with the largest U.S. randomized controlled trial of yoga to date, studying 228 adults—mostly Group Health patients.

“I think we’re seeing promise,” says Dr. Cherkin. “These are real-world results showing that both types of massage worked equally well to ease chronic back pain.”

They confirmed findings from their previous research by again linking yoga classes to better back-related function and diminished symptoms. In an Archives of Internal Medicine report e-published October 24, they also described surprising results: Intensive stretching classes had worked equally well.

Findings from the two path-breaking studies were featured by media outlets nationwide, including The New York Times, National Public Radio, ABC News, and CNN.

Visit us at: GroupHealthResearch.org to learn more about new findings and ongoing studies.

GHRI’s multi-disciplinary research spans these areas:

- Aging & geriatrics
- Alternative approaches to healing
- Behavior change
- Biostatistics
- Cancer control
- Cardiovascular health
- Child & adolescent health
- Chronic illness management
- Health informatics
- Health services & economics
- Immunization & infectious diseases
- Medication use & patient safety
- Mental health
- Obesity
- Preventive medicine
- Women’s health
Stability in a time of uncertainty: Group Health research addresses effectiveness and value

In an era of uncertainty for health care, federally funded research, and many other sectors of our nation’s economy, GHRI ended 2011 with annual grant revenues slightly higher than it had in 2010—and a stable outlook for 2012.

Much of our strength comes from grants for research in areas where we’ve long excelled. Our programs in cancer control, for example, have been tremendously successful, attracting many large awards for studies that can help determine the best approaches to prevention, screening, and early diagnosis. We also continue to break new ground in areas such as healthy aging, chronic illness care, mental health, vaccines, patient safety, and more. Meanwhile, we are bolstering our capacity in critical areas of health services research—partnering with others at Group Health and elsewhere to become a model learning health care system.

Selected major findings:
A sample of research articles published in 2011

Aging & geriatrics
Atrial fibrillation, the most common kind of irregular heartbeat, was associated with greater risk of dementia. (Journal of the American Geriatrics Society)

Depression at age 50 or older is linked to an increase in dementia and may be an early sign of the condition. (Archives of General Psychiatry)

Cancer
Using computer-aided detection in breast cancer screening did not significantly improve cancer-detection rates—but did raise the proportion of false-positive mammograms. (Journal of the National Cancer Institute)

Digital and film mammograms detected cancer at similar rates in women age 50 to 79 in a cohort study of health organizations across the United States. (Annals of Internal Medicine)

Cancer patients need more integration, patient-centered care, according to patient interviews and focus groups. Suggested solutions include providing patients with a care manager, computerized care integration and support, and reformatting provider reimbursement. (Quality & Safety in Health Care)

Cardiovascular health
Universal cholesterol screening for children and teens could result in 200,000 children and teens taking cholesterol-lowering drugs long-term, possibly causing side effects without necessarily preventing heart disease or death. (Journal of the American Medical Association)

Chronic illness
King County Steps to Health—a community-based initiative to prevent chronic disease—has helped address health disparities. (Health Education and Behavior)

Among thousands of Group Health patients with diabetes, those who also have depression are admitted to intensive care more often. (Psychosomatics)

Health information technology
According to the first randomized trial of its kind, using either a phone- or a Web-based smoking cessation intervention boosted quit rates, although study participants used phone services more often. Older age and the belief that certain treatments could improve predicted greater utilization across groups. (Nicotine & Tobacco Research)

Mental health
Online messaging can deliver organized follow-up care for depression effectively and efficiently. (Journal of General Internal Medicine)

A culturally tailored, Spanish-language version of Group Health’s phone-based cognitive behavioral therapy intervention was well accepted and linked to lower depression scores in a pilot study of 100 Latino patients in primary care. (Psychiatric Services)

Obesity and depression both dramatically increased health care costs, but they mainly acted separately. (Journal of General Internal Medicine)

Vaccines
A study of inactivated 2009 H1N1 vaccine in pregnant women reported an antibody response likely to give protection, with antibody also transferred to the fetus through the placenta. (Journal of Infectious Diseases)

Women’s health
Birth control pills may reduce a woman’s bone density. A study showed impacts on bone density were small, depended on the woman’s age and the hormone dose, and did not appear until about two years of use. (Journal of Clinical Endocrinology & Metabolism)

Healthy women who took the antidepressant escitalopram had fewer and less severe menopausal hot flashes than did those who took a placebo. (Journal of the American Medical Association)

For GHRI’s entire bibliography, go to: grouphealthresearch.org/research/publications/bibliography.aspx

Financial Statement

| Revenue | Federal grant and contract revenue | $37,262,284 |
| Other sponsored revenue | $6,227,169 |
| Group Health Cooperative support | $1,656,870 |
| Total revenues | $45,146,323 |
| Expense | Personnel expenses | $27,786,111 |
| Other expenses | $17,360,212 |
| Total expenses | $45,146,323 |
| Net gain/loss | $0 |

Research Advisory Board 2011

The Group Health Research Advisory Board assesses the quality, innovation, and relevance of Group Health research in enhancing quality of care and consumer value.

Rosemary Duchiwicz, MD, Senior Director, Parn Creek Timber Co., and Chair, Group Health Board of Trustees

Jerry Campbell, Group Health member; and Former Chair, Group Health Board of Trustees

Larry Corey, MD, President and Director, Fred Hutchinson Cancer Research Center

Mary L. “Nora” Dixis, MD, Professor of Medicine and Associate Dean, Translational Science, School of Medicine, University of Washington

Pam MacDwan, Former Executive Vice President, Public Affairs and Governance, Group Health

David McCulloch, MD, Medical Director, Clinical Improvement, Group Health

Laura Flehmgen, President, Group Health Foundation; and Vice President, Community Responsibility, Group Health

Dorothy Ruzicki, PhD, RN, Director of Educational Services, Providence Sacred Heart Medical Center

John Stattery, PhD, Vice Dean, Research & Graduate Education, School of Medicine; and Professor, Pharmacology and Medicine, University of Washington

Michael Soman, MD, MPH, Executive Medical Director, Group Health; and President and Chief Medical Executive, Group Health Physicians

John Steinle, MD, MPH, Senior Director, Kaiser Permanente Institute for Health Research

Walter F. “Buzz” Stewart, PhD, MPH, Director, Center for Health Research, Associate Chief Research Officer, Geisinger Health System

Michael Wanderer, MD, Family Practitioner, Group Health; and Former Chair, Group Health Physicians Board of Directors

GHRI revenue by sponsor

| 83% Federal | 13% Other | 4% Group Health |

| 2007 | $28.4 |
| 2008 | $33.6 |
| 2009 | $39.1 |
| 2010 | $42.2 |
| 2011 | $43.5 |

Active grants

| 2006 | 200 |
| 2007 | 233 |
| 2008 | 244 |
| 2009 | 252 |
| 2010 | 252 |
| 2011 | 271 |

Publications in peer-reviewed journals

| 2006 | 180 |
| 2007 | 188 |
| 2008 | 197 |
| 2009 | 261 |
| 2010 | 245 |
| 2011 | 256 |

Number of grants submitted

| 2006 | 73 |
| 2007 | 79 |
| 2008 | 102 |
| 2009 | 106 |
| 2010 | 109 |
| 2011 | 78 |

| Funded | Pending | Denied |
| 2006 | 53 | 126 |
| 2007 | 63 | 142 |
| 2008 | 74 | 176 |
| 2009 | 81 | 187 |
| 2010 | 85 | 194 |
| 2011 | 46 | 82 |
| Total | 206 |